CanBas Co., Ltd. (4575.T)
Tokyo · JPY · Healthcare · Biotechnology
¥737 (+0.14%) as of
Key statistics
- Market cap
- 14.52B
- EPS (TTM)
- -66.42
- Dividend yield
- 0.00%
- 52-week range
- 506.00 – 991.00
- Beta
- -0.83
- Profit margin
- 0.00%
- Volume
- 86.00k
About CanBas Co., Ltd.
CanBas Co., Ltd., a clinical stage biopharmaceutical company, engages in the basic research and clinical development of anti-cancer drugs. The company develops CBP501, a compound which regulates the regulatory function of the protein calmodulin in Phase 2 clinical trials targeting non-small cell lung cancer; and CBS9106 for patients with advanced solid tumors. CanBas Co., Ltd. was incorporated in 2000 and is based in Numazu, Japan.
- Sector
- Healthcare
- Industry
- Biotechnology
- Headquarters
- Numazu, Japan
- Employees
- 18
Financial statements (income statement, balance sheet, cash flow) and an interactive price chart are available on this page with JavaScript enabled.